ATE530182T1 - Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen - Google Patents
Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungenInfo
- Publication number
- ATE530182T1 ATE530182T1 AT08708027T AT08708027T ATE530182T1 AT E530182 T1 ATE530182 T1 AT E530182T1 AT 08708027 T AT08708027 T AT 08708027T AT 08708027 T AT08708027 T AT 08708027T AT E530182 T1 ATE530182 T1 AT E530182T1
- Authority
- AT
- Austria
- Prior art keywords
- 3alkyl
- ring
- nitrogen
- hydrogen
- sodium channel
- Prior art date
Links
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 title abstract 2
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 108010052164 Sodium Channels Proteins 0.000 title 1
- 102000018674 Sodium Channels Human genes 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 230000000903 blocking effect Effects 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 5
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- -1 haloC1-3alkyl Chemical group 0.000 abstract 2
- 229910052736 halogen Inorganic materials 0.000 abstract 2
- 150000002367 halogens Chemical class 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000019022 Mood disease Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000005864 Sulphur Substances 0.000 abstract 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 206010015037 epilepsy Diseases 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
- 229940125794 sodium channel blocker Drugs 0.000 abstract 1
- 239000003195 sodium channel blocking agent Substances 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0701365.9A GB0701365D0 (en) | 2007-01-24 | 2007-01-24 | Novel pharmaceutical compositions |
| PCT/EP2008/050623 WO2008090116A1 (en) | 2007-01-24 | 2008-01-21 | Novel pharmaceutical compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE530182T1 true ATE530182T1 (de) | 2011-11-15 |
Family
ID=37872716
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT08708027T ATE530182T1 (de) | 2007-01-24 | 2008-01-21 | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20090318530A1 (de) |
| EP (1) | EP2117535B1 (de) |
| JP (1) | JP2010516733A (de) |
| KR (1) | KR20090122933A (de) |
| CN (1) | CN101959513A (de) |
| AT (1) | ATE530182T1 (de) |
| AU (1) | AU2008208919A1 (de) |
| BR (1) | BRPI0808657A2 (de) |
| CA (1) | CA2676175A1 (de) |
| EA (1) | EA200970705A1 (de) |
| ES (1) | ES2374025T3 (de) |
| GB (1) | GB0701365D0 (de) |
| MX (1) | MX2009007914A (de) |
| WO (1) | WO2008090116A1 (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200728258A (en) | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (de) | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamidderivate als natriumkanalmodulatoren |
| WO2011015537A1 (en) * | 2009-08-05 | 2011-02-10 | Glaxo Group Limited | Co-therapy for the treatment of epilepsy and related disorders |
| EP2477964B1 (de) * | 2009-09-14 | 2015-02-11 | Convergence Pharmaceuticals Limited | Verfahren zur Herstellung von alpha-Carbonsäureamid-Derivaten |
| CN102188424B (zh) * | 2011-03-23 | 2013-03-27 | 浙江理工大学 | Sr140333的抗血癌作用 |
| GB201122113D0 (en) | 2011-12-22 | 2012-02-01 | Convergence Pharmaceuticals | Novel compounds |
| GB201209015D0 (en) | 2012-05-22 | 2012-07-04 | Convergence Pharmaceuticals | Novel compounds |
| EP3237379B1 (de) | 2014-12-23 | 2022-04-06 | Convergence Pharmaceuticals Limited | Verfahren zur herstellung von alpha-carboxamid-pyrrolidinderivaten |
| CN104865336B (zh) * | 2015-06-09 | 2017-04-12 | 成都百裕制药股份有限公司 | 高效液相色谱检测阿瑞匹坦中有关物质的方法 |
| CA3076823A1 (en) | 2017-10-05 | 2019-04-11 | Biogen Inc. | Process for preparing alpha-carboxamide pyrrolidine derivatives |
| MA50371A (fr) | 2017-10-10 | 2021-03-31 | Biogen Inc | Procédé de préparation de dérivés spiro |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL116249A (en) * | 1994-12-12 | 2003-07-06 | Pfizer | Nk-1 receptor antagonists for the treatment of neuronal damage and stroke |
| TW475930B (en) * | 1995-04-24 | 2002-02-11 | Novartis Ag | Novel compound, its use and pharmaceutical composition comprising it |
| TW200728258A (en) * | 2005-10-10 | 2007-08-01 | Glaxo Group Ltd | Novel compounds |
| TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
| EP1943216B1 (de) * | 2005-10-10 | 2010-06-30 | Glaxo Group Limited | Prolinamidderivate als natriumkanalmodulatoren |
-
2007
- 2007-01-24 GB GBGB0701365.9A patent/GB0701365D0/en not_active Ceased
-
2008
- 2008-01-21 KR KR1020097017501A patent/KR20090122933A/ko not_active Withdrawn
- 2008-01-21 JP JP2009546730A patent/JP2010516733A/ja active Pending
- 2008-01-21 AT AT08708027T patent/ATE530182T1/de not_active IP Right Cessation
- 2008-01-21 MX MX2009007914A patent/MX2009007914A/es unknown
- 2008-01-21 BR BRPI0808657-5A patent/BRPI0808657A2/pt not_active Application Discontinuation
- 2008-01-21 ES ES08708027T patent/ES2374025T3/es active Active
- 2008-01-21 WO PCT/EP2008/050623 patent/WO2008090116A1/en not_active Ceased
- 2008-01-21 CA CA002676175A patent/CA2676175A1/en not_active Abandoned
- 2008-01-21 AU AU2008208919A patent/AU2008208919A1/en not_active Abandoned
- 2008-01-21 EP EP08708027A patent/EP2117535B1/de not_active Not-in-force
- 2008-01-21 EA EA200970705A patent/EA200970705A1/ru unknown
- 2008-01-21 CN CN2008800097508A patent/CN101959513A/zh active Pending
- 2008-01-21 US US12/524,422 patent/US20090318530A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2117535B1 (de) | 2011-10-26 |
| CA2676175A1 (en) | 2008-07-31 |
| WO2008090116A1 (en) | 2008-07-31 |
| CN101959513A (zh) | 2011-01-26 |
| KR20090122933A (ko) | 2009-12-01 |
| EP2117535A1 (de) | 2009-11-18 |
| ES2374025T3 (es) | 2012-02-13 |
| GB0701365D0 (en) | 2007-03-07 |
| MX2009007914A (es) | 2009-07-31 |
| US20090318530A1 (en) | 2009-12-24 |
| JP2010516733A (ja) | 2010-05-20 |
| AU2008208919A1 (en) | 2008-07-31 |
| EA200970705A1 (ru) | 2010-02-26 |
| BRPI0808657A2 (pt) | 2014-08-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE530182T1 (de) | Pharmazeutische zubereitungen enthaltend nk1- rezeptoren antagonisten und natriumkanal blockierende verbindungen | |
| ATE530187T1 (de) | Pharmazeutische zubereitungen mit nk1-rezeptor- antagonisten und natriumkanalblockern | |
| DE60320012D1 (de) | Aminoheterocyclen als vr-1 antagonisten zur behandlung von schmerzen | |
| TWI262917B (en) | 2-Furancarboxylic hydrazides and pharmaceutical compositions containing the same | |
| DE602006009773D1 (de) | Substituierte thiophenderivate als glucagonrezeptorantagonisten, herstellung und therapeutische anwendungen | |
| IS8503A (is) | Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar | |
| EP1361220A4 (de) | Cyclische verbindungen mit thrombopoietinrezeporagonismus | |
| TW200726765A (en) | Triazolopyridine cannabinoid receptor 1 antagonists | |
| EA201101398A1 (ru) | Замещенные пиперидины в качестве антагонистов ccr3 | |
| EA200700099A1 (ru) | Производные пиридина | |
| TW200716528A (en) | Cyclopropanecarboxamide derivatives | |
| NO20064579L (no) | Bifenylforbindelser anvendelige som muskariniske receptorantagonister | |
| EA200970706A1 (ru) | Новые фармацевтические композиции | |
| DK1786790T3 (da) | Oxazolderivater som histamin H3 receptorstoffer, fremstilling og terapeutiske anvendelser | |
| ECSP10010414A (es) | Compuestos tricíclicos que tienen actividad antagonista de factor de liberación de corticotropina y composiciones farmacéuticas que contienen los mismos | |
| AR072809A1 (es) | Compuesto de (3- piridinilcarbonil)-4-(fenilsulfonilpiperazina ), su uso para la elaboracion de unmedicamento para el tratamiento del dolor y composicion farmaceutica que lo comprende | |
| ATE459619T1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| EA200700027A1 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
| DE602004023926D1 (de) | Selektive spirocyclische glucocorticoid-rezeptor-modulatoren | |
| MX393201B (es) | Inhibidores novedosos de glutaminil ciclasa y el uso de los mismos en el tratamiento de diversas enfermedades | |
| DE602006015509D1 (de) | Glucagonrezeptorantagonisten, deren herstellung und therapeutische verwendung | |
| AR054508A1 (es) | Compuesto de bencilpiperazina, su uso para preparar un medicamento, procedimientos para la preparacion de dicho compuesto y de compuestos intermediarios, dichos compuestos intermediarios, composicion farmaceutica que lo comprende y procedimiento para prepararla | |
| MX2009012933A (es) | Derivados de ariloxazol ariloxadiazol y bencimidazol como moduladores de la actividad del receptor de somatostatinas. | |
| EA201071259A1 (ru) | Спиро(пиперидин-4,2-пирролидин)-1-(3,5-трифторметилфенил)метилкарбоксамиды в качестве антагонистов рецептора nk1 тахикинина | |
| AR071487A1 (es) | Derivados de (5r)-1,5-diaril-4,5-dihidro-1h-pirazol-3-carboxamidina que tienen actividad antagonista cb1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |